Pharmaceutical
Innovation in the pharmaceutical industry means absolutely nothing without a tangible human impact. That’s why Aixial continuously shapes the future of modern medicine, leveraging clinical expertise to build a healthier, safer, and more sustainable tomorrow.
The pharmaceutical industry is driven by one mission:
Delivering safe and high-quality treatments to patients worldwide
Pharmaceutical organisations operate within a highly complex and interconnected ecosystem shaped by strict regulation and continuous scientific progress. Today, advances in biotechnology, data science, and manufacturing are enabling more targeted, effective, and personalised treatments. As a result, the industry remains highly dynamic and strategically important worldwide.
Aixial in pharmaceutical industry
Navigating the future of clinical development
The pharmaceutical industry faces a highly complex and demanding environment. Today, life sciences companies must navigate strict regulatory compliance, exponential data growth, and rising quality standards.
At the same time, the pressure to accelerate clinical trials and improve operational efficiency is intense. Adapting to modern science requires a major shift toward pharma digital transformation, strong data integrity, and agile operations.
Why choose Aixial as your pharmaceutical CRO partner?
Aixial delivers specialised consulting and operational expertise across the entire clinical trial lifecycle. To achieve this, we work to boost efficiency, guarantee regulatory compliance, and optimise workflows.
Consequently, our 8 core expertise areas help clients overcome complex challenges. Through flexible consulting and FSP models, organisations gain seamless access to tailored expertise aligned with their strategic priorities.
Our areas of expertise
Biometry
Clinical operation
Medical writing
Pharmacovigilance
Quality assurance
HEOR & market acces
Medical & regulatory affairs
Toxicology
To learn more about our positioning within the industry
Clinical expertise across therapeutic areas
At Aixial Group, we accelerate clinical development with specialized talent and advanced processes, backed by global experience across 1,580+ programs spanning Phase I-IV, First-in-Human, and RWE.
Oncology: Advanced trial designs (biomarker-driven, crossover) to accelerate personalised medicine.
Rare Diseases: Specialised regulatory pathways and KOL networks for niche orphan indications.
Central Nervous System (CNS): Strong clinical track record in Alzheimer’s, Parkinson’s, MS, and ALS.
Vaccines: Extensive capabilities in prophylactic and therapeutic vaccine trials, managing large-scale cohorts, complex immunogenicity endpoints, and rapid deployment strategies.
Other Specialties: Deep therapeutic understanding across multiple disciplines.
Benefits to partnering with us
Reduce HR burden
We handle recruitment and resource management in-house. This dedicated talent acquisition capability allows us to rapidly scale qualified clinical teams, ensuring seamless operational support and flexible FSP models.
Increase value for money
You pay strictly for the service and deliverables you need. This approach eliminates overhead costs, allowing you to maximise your clinical trial budgets through highly efficient, scalable resource models.
Develop economies of scale
We achieve productivity gains by operating tasks at high volume. Consequently, this optimised workflow reduces your operational costs while driving greater efficiency across your clinical programs.
Transfer risks
Through fixed-price packages, we assume part of the risks associated with the delivery. Thereby, you secure predictable clinical trial costs while ensuring high-quality, on-time project execution.
Q&A
What makes Aixial a unique pharmaceutical CRO partner?
Aixial stands out by seamlessly bridging the gap between high-level strategic consulting and robust operational support. Besides, because we understand that a one-size-fits-all approach fails to meet modern industry demands, we actively customize our services to match the exact strategic priorities and scaling needs of each client.
Which therapeutic areas in the pharmaceutical sector are your primary focus?
While we support global trials across more than 20 therapeutic areas, our core clinical and scientific expertise lies in complex and specialised modalities specifically:
Oncology (Early-phase to global multi-site trials)
Rare diseases (Patient-centric strategies for small, highly targeted cohorts)
Central Nervous System (CNS) (Neurodegenerative and chronic disorders)
Other specialty therapeutics
What engagement models does Aixial Group offer to pharma companies?
We understand that different projects require different levels of outsourcing. Accordingly, we provide three flexible operational models:
Consulting support: On-demand high-level strategic, regulatory, or medical writing expertise.
Full-Service CRO partnership: Managing your clinical trial end-to-end with our teams, technology, and project governance.
Functional Service Provision (FSP): Supplying dedicated, expert teams embedded into your own infrastructure to scale up specific functions (e.g., Biostatistics, Data Management, or Pharmacovigilance).
What is the difference between your flexible consulting and FSP models?
Understanding that resource needs fluctuate throughout a study, we offer distinct delivery frameworks designed to optimize operational efficiency and control costs. On one hand, our consulting support provides on-demand, high-level expertise for ad-hoc regulatory or strategic challenges; on the other hand, our Functional Service Provision (FSP) models grant organizations dedicated, long-term operational teams that seamlessly integrate into their existing internal workflows.
What clinical development phases does Aixial Group cover for pharmaceutical sponsors?
Aixial Group provides comprehensive CRO services covering the entire clinical trial lifecycle, from Phase I (including First-in-Human trials) through Phases II–III, to Phase IV and post-marketing surveillance. Indeed, with over 30 years of experience, we adapt our operational framework to suit the specific requirements of each phase while maintaining the highest quality standards.
Can Aixial Group manage global safety and pharmacovigilance (PV) for marketed pharmaceutical products?
Yes. We offer comprehensive, end-to-end vigilance services for both investigational drugs and post-marketing portfolios. Specifically, our services include processing Individual Case Safety Reports (ICSR), managing safety databases, medical review, signal detection, and QPPV (Qualified Person for Pharmacovigilance) support, ensuring 24/7 global compliance.
How does Aixial ensure compliance with strict pharmaceutical regulations globally?
Compliance and data integrity are at the heart of our operations. Therefore, Aixial Group operates under a robust Quality Management System (QMS) and maintains its ISO 9001:2015 certification across all critical functions, including clinical operations, biometrics, regulatory affairs, and vigilance.
Does Aixial Group provide medical writing services for pharmaceutical regulatory submissions?
Absolutely. Our highly qualified team of scientific and medical writers produces clear, concise, and compliant documentation. Namely, this includes clinical study protocols, investigator’s brochures (IB), clinical study reports (CSR), and common technical document (CTD) modules required for marketing authorization applications.
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.
